Another COVID Toll: Over 134,000 Undiagnosed Cancers During Height of Pandemic Diagnosis rates remained low throughout 2020, with mortality increase projected Feb 22, 2024
Arginine Starvation Boosts OS in Mesothelioma With frontline immunotherapy now standard, strategy could potentially find home in second-line Feb 16, 2024
Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC But how well will the results from China translate to Western populations? Feb 16, 2024
Tepotinib Gains Full Approval for Metastatic NSCLC Agency converts accelerated approval for subset with MET exon 14 mutations Feb 16, 2024
Smokers Who Quit and Stick With It See Greatest Reduction in Cancer Risk Cessation at any age proved helpful for lowering cancer risk Feb 06, 2024
Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs "If the patients are not taking the drug, then it's not going to work" Feb 06, 2024
Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
Pushback on Rule for Surgical Lymph Node Sampling During Lung Resection Surgeons debate the right standard for lymph node dissection in lung cancer Jan 31, 2024
How Can Cancer Risk Be Cut in Communities Exposed to Toxins? Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk Findings don't tell us to stop these drugs, researcher says, but should guide clinical decisions Jan 13, 2024
Hypofractionated Chemoradiation With Adaptive SABR Appeared Effective in NSCLC Dose of 70 Gy in 15 fractions showed favorable balance between safety and efficacy in small trial Jan 12, 2024
Cryobiopsy and Forceps Biopsy Go Head-to-Head for Diagnosing Lung Lesions When added to needle aspiration, one method yielded better samples for molecular testing in NSCLC Jan 09, 2024
Futile Immunotherapy for Cancer Grows More Common Occurs most often at non-academic and low-volume centers Jan 04, 2024
Cancer Patients Face Frightening Delays in Treatment Approvals "For them to take weeks -- up to months -- to provide an authorization is ridiculous" Dec 30, 2023
Homelessness Tied to Worse Cancer Outcomes Among Veterans However, all-cause mortality rates in lung, colon cancer lower versus other healthcare settings Dec 21, 2023
Grappling With Our Deadliest Cancer Here are essential steps to improve lung cancer screening Dec 10, 2023
With an Old X-Ray, AI Can Detect High Risk of Lung Cancer in Never Smokers Tool could identify nonsmokers most likely to benefit from low-dose CT screening Nov 29, 2023
Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations Researchers suggest the drug is a promising option for this rare subgroup Nov 22, 2023
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer Drug achieved high response rates in TKI-naive and TKI-pretreated patients Nov 16, 2023
Lung Cancer Survival High at 20 Years With Screen-Detected Tumors After two decades, lung cancer-specific survival remained at 81% in I-ELCAP program Nov 07, 2023
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S. Findings suggest patients with SCLC are not screened for LEMS, despite their association Nov 02, 2023
ACS: Millions More Should Get Lung Cancer Screening Notably, new recommendations say it doesn't matter when a person quit smoking Nov 01, 2023
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3 Oct 30, 2023 video
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC Amivantamab-based regimens improved oncologic outcomes, but with more side effects Oct 25, 2023
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
Targeting KRAS in NSCLC: Recent Progress and New Approaches Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
Pembrolizumab Wins FDA Approval in Operable Lung Cancer Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
New Lung Cancer Cases Are Higher in Younger Women vs Men And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
Primary Care Intervention Improved Follow-Up of Abnormal Cancer Screening Results Follow-up testing within 120 days was improved with EHR reminders, patient outreach, navigation Oct 10, 2023
Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel But agency doesn't plan to immediately push for KRAS inhibitor's withdrawal Oct 05, 2023
Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over "systemic bias" Oct 04, 2023
The White House Cancer Moonshot Is a Dud We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
Individualized SABR for Lung Tumors Yields Low Recurrence Rates Strategy also results in low rates of severe toxic effects Sep 14, 2023
